Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids - Takeaways - MDSpire

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids

  • By

  • Fan Zhang

  • Yuxiang Wang

  • Xi Zhang

  • Yuting Bai

  • Li Zhang

  • Shuqing Wei

  • May 12, 2026

  • 0 min

Share

  • 1

    Lung cancer is the most common cancer and leading cause of cancer deaths globally, with poor prognosis despite treatment advances.

  • 2

    A 52-year-old woman with advanced lung adenocarcinoma and EGFR exon 21 L858R mutations achieved partial response after PDTO-guided therapy.

  • 3

    Initial treatment with Osimertinib failed, leading to multiple subsequent therapies before utilizing patient-derived tumor organoids.

  • 4

    Patient-derived tumor organoids serve as a valuable platform for personalized treatment selection and drug sensitivity testing.

  • 5

    This case highlights the potential of organoid technology to optimize clinical outcomes for heavily pretreated lung cancer patients.

Original Source(s)

Case Report: Personalized treatment in an advanced lung adenocarcinoma patient with EGFR exon 21 L858R mutations based on the patient-derived tumor organoids

  • by Fan Zhang, Yuxiang Wang, Xi Zhang, Yuting Bai, Li Zhang, Shuqing Wei

  • May 12, 2026

Related Content

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma